Gastric Cancer
Conditions
Brief summary
Objective Response (OR) according to RECIST v1.1 as assessed by Investigators.
Detailed description
Number of Participants with Adverse Events (AEs) and Treatment Related AEs., Duration of Response (DoR) according to RECIST v1.1 as assessed by Investigators., Number of Participants with Disease Control., Time to Response according to RECIST v1.1 as assessed by Investigators., Progression-free Survival (PFS) according to RECIST v1.1 as assessed by Investigators., Pharmacokinetic (PK) Plasma Concentrations of M9140., Number of Participants with Anti-Drug Antibodies (ADA) against M9140., CEACAM5 expression in tumor.
Interventions
DRUGM9140
Sponsors
Merck Healthcare KGaA
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response (OR) according to RECIST v1.1 as assessed by Investigators. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Adverse Events (AEs) and Treatment Related AEs., Duration of Response (DoR) according to RECIST v1.1 as assessed by Investigators., Number of Participants with Disease Control., Time to Response according to RECIST v1.1 as assessed by Investigators., Progression-free Survival (PFS) according to RECIST v1.1 as assessed by Investigators., Pharmacokinetic (PK) Plasma Concentrations of M9140., Number of Participants with Anti-Drug Antibodies (ADA) against M9140., CEACAM5 expression in tumor. | — |
Countries
Austria, France, Germany, Italy, Spain
Outcome results
None listed